Evidence map›Paper›PMID 34658383›Full record

ArticleBiometrika2021

A parsimonious personalized dose-finding model via dimension reduction.

Wenzhuo Zhou, Ruoqing Zhu, Donglin Zeng

Abstract read
In one paragraph

Article in Biometrika, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A single-index model with a surface-link for optimizing individualized dose rules.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wenzhuo ZhouDepartment of Statistics, University of Illinois at Urbana-Champaign, Champaign, Illinois 61820, U.S.A.
Ruoqing ZhuDepartment of Statistics, University of Illinois at Urbana-Champaign, Champaign, Illinois 61820, U.S.A.
Donglin ZengDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, U.S.A.

Funding

Statistical and Machine Learning Methods to Improve Dynamic Treatment Regimens Estimation Using Real World Data.R01GM124104 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yuanjia Wang, Donglin Zeng · 2018 to 2026
$3.1M
Machine Learning Methods for Optimizing Individualized Treatment Strategies for Precision PsychiatryR01MH123487 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WANG, YUANJIA · 2021 to 2025
$2.0M
Semiparametric Analysis of Big Censored DataR01HL149683 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIN, DANYU · 2020 to 2023
$1.9M
NHLBI NIH HHS R01 HL149683NIGMS NIH HHS R01 GM124104NIMH NIH HHS R01 MH123487
6 · The paper itself

Abstract

Learning an individualized dose rule in personalized medicine is a challenging statistical problem. Existing methods often suffer from the curse of dimensionality, especially when the decision function is estimated nonparametrically. To tackle this problem, we propose a dimension reduction framework that effectively reduces the estimation to a lower-dimensional subspace of the covariates. We exploit that the individualized dose rule can be defined in a subspace spanned by a few linear combinations of the covariates, leading to a more parsimonious model. Also, our framework does not require the inverse probability of the propensity score under observational studies due to a direct maximization of the value function. This distinguishes us from the outcome weighted learning framework, which also solves decision rules directly. Under the same framework, we further propose a pseudo-direct learning approach focuses more on estimating the dimensionality-reduced subspace of the treatment outcome. Parameters in both approaches can be estimated efficiently using an orthogonality constrained optimization algorithm on the Stiefel manifold. Under mild regularity assumptions, the asymptotic normality results of the proposed estimators can are established, respectively. We also derive the consistency and convergence rate for the value function under the estimated optimal dose rule. We evaluate the performance of the proposed approaches through extensive simulation studies and a warfarin pharmacogenetic dataset.

Indexed as

Dimension ReductionDirect LearningIndividualized Dose RulePropensity ScoreSemiparametric InferenceStiefel Manifold

Identifiers

PMID34658383
PMCPMC8514170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.